[Classification of malignant lymphomas--current status and clinical implications]

Area of Science:

• Hematology
• Oncology
• Pathology

Context:

• Advances in cytogenetics, molecular biology, and immunology have revolutionized understanding of malignant lymphomas.
• These advancements necessitate a reevaluation of existing lymphoma classifications.
• The Revised European-American Lymphoma (R.E.A.L.) classification emerged from this evolving scientific landscape.

Purpose:

• To introduce the R.E.A.L. classification, a biologically and pathologically driven system for lymphoid malignancies.
• To present a clinical grouping framework for R.E.A.L. lymphoma subtypes to facilitate practical application.
• To establish a foundation for international collaboration in lymphoma research and treatment.

Summary:

• The R.E.A.L. classification, based on new biological insights, redefines lymphoid malignancies.
• A clinical grouping categorizes R.E.A.L. subtypes into indolent, aggressive, very aggressive, and Hodgkin lymphoma.
• This consensus represents a significant step towards standardized lymphoma management and cooperative studies.

Impact:

• Facilitates international cooperation in the management of malignant lymphomas.
• Provides a basis for cooperative clinical studies to improve treatment strategies.
• Offers hope for future advancements in the treatment of malignant lymphomas.